Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 35.841 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US45784P1012
State: 03.04.2025 | 12AM
Do you already know our new terminal view? Click here.
FIGI: BBG000R7XX87
PODD
Insulet Corporation
GICS: - · Sector: Healthcare · Sub-Sector: Medical Devices
NAME
Insulet Corporation
ISIN
US45784P1012
TICKER
PODD
MIC
XNAS
REUTERS
PODD.OQ
BLOOMBERG
PODD US
Wed, 19.03.2025       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared new Omnipod 5 clinical data from its RADIANT study. Results from this multinational randomized controlled trial were presented at the 18th International Conference on Advanced Technolo...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Tue, 18.03.2025       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”). The Notes will bear interest at an annual rate of 6.50% and will matu...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Tue, 18.03.2025       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”) in a private placement. ...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Tue, 18.03.2025       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its revolutionary Omnipod 5 Automated Insulin Delivery (AID) System is now available in Australia and will soon be offered in three additional countries, helping transform the lives...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Tue, 18.03.2025       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Tue, 11.03.2025       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the E...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Thu, 20.02.2025       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones a...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Mon, 13.01.2025       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden. Omnipod 5 is now available with b...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Fri, 10.01.2025       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, m...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.12.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (“EOFlow") in federal court. After a four-week trial in the U.S. District Court for the District of ...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Wed, 20.11.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipo...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Fri, 15.11.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 1...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Thu, 07.11.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. “We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chi...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Fri, 01.11.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to recognize National Diabetes Awareness Month and World Diabetes Day with a series of activities in November. “People with diabetes must make dozens of decisions every day t...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Tue, 29.10.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the full market release of the Omnipod 5 App for iPhone® in the U.S. Now available to download for free on the Apple App Store, the App allows users to fully control their Omnipod ...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Mon, 30.09.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will ho...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Mon, 26.08.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it t...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Tue, 20.08.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 2024 Wells Fargo Healthcare Conference in Boston on Wednesday, September 4, 2024 at 9:30 a.m. The ...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Wed, 14.08.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted a grand opening celebration at its new manufacturing facility in Johor Bahru, Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.co...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink
Thu, 08.08.2024       Insulet
US45784P1012

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of $488.5 million, up 23.2%, or 23.4% in constant c...
Read More
Insulet
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.